Abstract
COVID-19 morbidity and mortality are increased via unknown mechanisms in patients with diabetes and kidney disease. SARS-CoV-2 uses angiotensin-converting enzyme 2 (ACE2) for entry into host cells. Because ACE2 is a susceptibility factor for infection, we investigated how diabetic kidney disease and medications alter ACE2 receptor expression in kidneys. Single cell RNA profiling of kidney biopsies from healthy living donors and patients with diabetic kidney disease revealed ACE2 expression primarily in proximal tubular epithelial cells. This cell-specific localization was confirmed by in situ hybridization. ACE2 expression levels were unaltered by exposures to renin-angiotensin-aldosterone system inhibitors in diabetic kidney disease. Bayesian integrative analysis of a large compendium of public -omics datasets identified molecular network modules induced in ACE2-expressing proximal tubular epithelial cells in diabetic kidney disease (searchable at hb.flatironinstitute.org/covid-kidney) that were linked to viral entry, immune activation, endomembrane reorganization, and RNA processing. The diabetic kidney disease ACE2-positive proximal tubular epithelial cell module overlapped with expression patterns seen in SARS-CoV-2–infected cells. Similar cellular programs were seen in ACE2-positive proximal tubular epithelial cells obtained from urine samples of 13 hospitalized patients with COVID-19, suggesting a consistent ACE2-coregulated proximal tubular epithelial cell expression program that may interact with the SARS-CoV-2 infection processes. Thus SARS-CoV-2 receptor networks can seed further research into risk stratification and therapeutic strategies for COVID-19–related kidney damage.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1502-1518 |
| Number of pages | 17 |
| Journal | Kidney International |
| Volume | 98 |
| Issue number | 6 |
| DOIs | |
| State | Published - Dec 2020 |
All Science Journal Classification (ASJC) codes
- Nephrology
Keywords
- ACE inhibitors
- COVID-19
- SARS-CoV-2
- acute kidney injury
- diabetic nephropathy
- molecular networks
- proximal tubules
- scRNAseq
Access to Document
Other files and links
Fingerprint Dive into the research topics of 'SARS-CoV-2 receptor networks in diabetic and COVID-19–associated kidney disease'. Together they form a unique fingerprint.
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
SARS-CoV-2 receptor networks in diabetic and COVID-19–associated kidney disease. / Menon, Rajasree; Otto, Edgar A.; Sealfon, Rachel; Nair, Viji; Wong, Aaron K.; Theesfeld, Chandra L.; Chen, Xi; Wang, Yuan; Boppana, Avinash S.; Luo, Jinghui; Yang, Yingbao; Kasson, Peter M.; Schaub, Jennifer A.; Berthier, Celine C.; Eddy, Sean; Lienczewski, Chrysta C.; Godfrey, Bradley; Dagenais, Susan L.; Sohaney, Ryann; Hartman, John; Fermin, Damian; Subramanian, Lalita; Looker, Helen C.; Harder, Jennifer L.; Mariani, Laura H.; Hodgin, Jeffrey B.; Sexton, Jonathan Z.; Wobus, Christiane E.; Naik, Abhijit S.; Nelson, Robert G.; Troyanskaya, Olga G.; Kretzler, Matthias.
In: Kidney International, Vol. 98, No. 6, 12.2020, p. 1502-1518.Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - SARS-CoV-2 receptor networks in diabetic and COVID-19–associated kidney disease
AU - Menon, Rajasree
AU - Otto, Edgar A.
AU - Sealfon, Rachel
AU - Nair, Viji
AU - Wong, Aaron K.
AU - Theesfeld, Chandra L.
AU - Chen, Xi
AU - Wang, Yuan
AU - Boppana, Avinash S.
AU - Luo, Jinghui
AU - Yang, Yingbao
AU - Kasson, Peter M.
AU - Schaub, Jennifer A.
AU - Berthier, Celine C.
AU - Eddy, Sean
AU - Lienczewski, Chrysta C.
AU - Godfrey, Bradley
AU - Dagenais, Susan L.
AU - Sohaney, Ryann
AU - Hartman, John
AU - Fermin, Damian
AU - Subramanian, Lalita
AU - Looker, Helen C.
AU - Harder, Jennifer L.
AU - Mariani, Laura H.
AU - Hodgin, Jeffrey B.
AU - Sexton, Jonathan Z.
AU - Wobus, Christiane E.
AU - Naik, Abhijit S.
AU - Nelson, Robert G.
AU - Troyanskaya, Olga G.
AU - Kretzler, Matthias
N1 - Funding Information: This work was supported in part by the Intramural Research Program at the National Institute of Diabetes and Digestive and Kidney Diseases ( DK069062 to HCL and RGN; DK083912 , DK082841 , DK020572 , and DK092926 to RGK), the extramural research program of the National Institute of Diabetes and Digestive and Kidney Diseases R24 DK082841 “ Integrated Systems Biology Approach to Diabetic Microvascular Complications ” and P30 DK081943 “ University of Michigan O'Brien Kidney Translational Core Center ” to MK, via the “Kidney Precision Medicine Project” (KPMP, funded by the following grants from the NIDDK : U2C DK114886 , UH3DK114861 , UH3DK114866 , UH3DK114870 , UH3DK114908 , UH3DK114915 , UH3DK114926 , UH3DK114907 , UH3DK114920 , UH3DK114923 , UH3DK114933 , and UH3DK114937 , with U2C DK114886 and UH3 DK114907 ) to MK and OGT, via the Chan Zuckerberg Initiative “Human Cell Atlas Kidney Seed Network” to MK and OGT, JDRF 5-COE-2019-861-S-B “JDRF and M-Diabetes Center of Excellence at the University of Michigan” to MK, and a COVID grant from amFAR , the Foundation for AIDS Research , to MK. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Funding Information: The authors thank Lois Jones, RN, Enrique Diaz, RN, Bernadine Waseta, and Camille Waseta for performing the studies in the diabetes cohort and the University of Michigan Advanced Genomics Core for providing expert technical assistance with single-cell processing and sequencing. They also thank Dr. Carmen Mirabelli for reviewing this manuscript and providing valuable feedback. This work was supported in part by the Intramural Research Program at the National Institute of Diabetes and Digestive and Kidney Diseases (DK069062 to HCL and RGN; DK083912, DK082841, DK020572, and DK092926 to RGK), the extramural research program of the National Institute of Diabetes and Digestive and Kidney Diseases R24 DK082841 ?Integrated Systems Biology Approach to Diabetic Microvascular Complications? and P30 DK081943 ?University of Michigan O'Brien Kidney Translational Core Center? to MK, via the ?Kidney Precision Medicine Project? (KPMP, funded by the following grants from the NIDDK: U2C DK114886, UH3DK114861, UH3DK114866, UH3DK114870, UH3DK114908, UH3DK114915, UH3DK114926, UH3DK114907, UH3DK114920, UH3DK114923, UH3DK114933, and UH3DK114937, with U2C DK114886 and UH3 DK114907) to MK and OGT, via the Chan Zuckerberg Initiative ?Human Cell Atlas Kidney Seed Network? to MK and OGT, JDRF 5-COE-2019-861-S-B ?JDRF and M-Diabetes Center of Excellence at the University of Michigan? to MK, and a COVID grant from amFAR, the Foundation for AIDS Research, to MK. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. We acknowledge the Kidney Precision Medicine Project represented by the following members: American Association of Kidney Patients, Tampa, FL: Richard Knight; Beth Israel Deaconess, Boston, MA: Stewart Lecker, Isaac Stillman; Boston University, Boston, MA: Sushrut Waikar; Brigham and Women's Hospital, Boston, MA: Gearoid McMahon, Astrid Weins, Samuel Short; Broad Institute, Cambridge, MA: Nir Hacohen, Paul Hoover; Case Western Reserve, Cleveland, OH: Mark Aulisio; Cleveland Clinic, Cleveland, OH: Leslie Cooperman, Leal Herlitz, John O'Toole, Emilio Poggio, John Sedor, Stacey Jolly; Columbia University, New York, NY: Paul Appelbaum, Olivia Balderes, Jonathan Barasch, Andrew Bomback, Pietro A. Canetta, Vivette D. d'Agati, Krzysztof Kiryluk, Satoru Kudose, Karla Mehl, Jai Radhakrishnan, Chenhua Weng; Duke University, Durham, NC: Laura Barisoni; European Molecular Biology Laboratory, Heidelberg, Germany: Theodore Alexandrov; Indiana University, Indianapolis, IN: Tarek Ashkar, Daria Barwinska, Pierre Dagher, Kenneth Dunn, Michael Eadon, Michael Ferkowicz, Katherine Kelly, Timothy Sutton, Seth Winfree; John Hopkins University, Baltimore, MD: Steven Menez, Chirag Parikh, Avi Rosenberg, Pam Villalobos, Rubab Malik, Derek Fine, Mohammed Atta, Jose Manuel Monroy Trujillo; Joslin Diabetes Center, Boston, MA: Alison Slack, Sylvia Rosas, Mark Williams; Mount Sinai, New York, NY: Evren Azeloglu, Cijang (John) He, Ravi Iyengar, Jens Hansen; Ohio State University, Columbus, OH: Samir Parikh, Brad Rovin; Pacific Northwest National Laboratories, Richland, WA: Chris Anderton, Ljiljana Pasa-Tolic, Dusan Velickovic, Jessica Lukowski; Parkland Center for Clinical Innovation, Dallas, TX: George (Holt) Oliver; Patient Partners: Joseph Ardayfio, Jack Bebiak, Keith Brown, Taneisha Campbell, Catherine Campbell, Lynda Hayashi, Nichole Jefferson, Robert Koewler, Glenda Roberts, John Saul, Anna Shpigel, Edith Christine Stutzke, Lorenda Wright, Leslie Miegs, Roy Pinkeney; Princeton University, Princeton, NJ: Rachel Sealfon, Olga Troyanskaya; Providence Medical Research Center, Providence Health Care, Spokane, WA: Katherine Tuttle; Stanford University, Palo Alto, CA: Dejan Dobi, Yury Goltsev; University of California San Diego, La Jolla, CA: Blue Lake, Kun Zhang; University of California San Francisco, San Francisco, CA: Maria Joanes, Zoltan Laszik, Andrew Schroeder, Minnie Sarwal, Tara Sigdel; University of Michigan, Ann Arbor, MI: Ulysses Balis, Victoria Blanc, Oliver He, Jeffrey Hodgin, Matthias Kretzler, Laura Mariani, Rajasree Menon, Edgar Otto, Jennifer Schaub, Becky Steck, Chrysta Lienczewski, Sean Eddy; University of Pittsburgh, Pittsburgh, PA: Michele Elder, Daniel Hall, John Kellum, Mary Kruth, Raghav Murugan, Paul Palevsky, Parmjeet Randhawa, Matthew Rosengart, Sunny Sims-Lucas, Mary Stefanick, Stacy Stull, Mitchell Tublin; University of Washington, Seattle, WA: Charles Alpers, Ian de Boer, Ashveena Dighe, Jonathan Himmelfarb, Robyn Mcclelland, Sean Mooney, Stuart Shankland, Kayleen Williams, Kristina Blank, Jonas Carson, Frederick Dowd, Zach Drager, Christopher Park; UT Health San Antonio, Center for Renal Precision Medicine, San Antonio, TX: Kumar Sharma, Guanshi Zhang, Shweta Bansal, Manjeri Venkatachalam; UT Southwestern Medical Center, Dallas, TX: Asra Kermani, Simon Lee, Christopher Lu, Tyler Miller, Orson Moe, Harold Park, Kamalanathan Sambandam, Francisco Sanchez, Jose Torrealba, Toto Robert, Miguel Vazquez, Nancy Wang; Washington University, St. Louis, MO: Joe Gaut, Sanjay Jain, Anitha Vijayan; and Yale University, New Haven, CT: Randy Luciano, Dennis Moledina, Ugwuowo Ugochukwu, Francis Perry Wilson, Sandy Alfano. Funding Information: MK reports grants from the National Institutes of Health (NIH) and nonfinancial support from the University of Michigan during the conduct of the study as well as grants from JDRF, Astra-Zeneca, NovoNordisk, Eli Lilly, Gilead, Goldfinch Bio, Merck, Chan Zuckerberg Initiative, Janssen, Boehringer-Ingelheim, Moderna, Chinook, amfAR, Angion, RenalytixAI, Retrophin, the European Union Innovative Medicine Initiative, and Certa outside of the submitted work, and has licensed patent PCT/EP2014/073413 “Biomarkers and methods for progression prediction for chronic kidney disease.” OT reports serving on the scientific advisory boards of Caris Life Sciences and GoldFinch Bio, both outside of the submitted work. LHM reports grants from NIH–National Institute of Diabetes and Digestive and Kidney Diseases and the National Center for Advancing Translational Sciences during the conduct of the study and other research funding from Boehringer Ingelheim, serves on the Reata Pharmaceutical CKD Advisory Board, and has received honoraria for American Society of Nephrology Board Review. SE has served as coinvestigator on grants funded by Gilead Sciences, NovoNordisk, Astra-Zeneca, Jannsen, and Eli Lilly. ASN reports funding from the Michigan Institute of Clinical Health Research, Novartis, and the National Institute of Allergy and Infectious Diseases. Publisher Copyright: © 2020 International Society of Nephrology
PY - 2020/12
Y1 - 2020/12
N2 - COVID-19 morbidity and mortality are increased via unknown mechanisms in patients with diabetes and kidney disease. SARS-CoV-2 uses angiotensin-converting enzyme 2 (ACE2) for entry into host cells. Because ACE2 is a susceptibility factor for infection, we investigated how diabetic kidney disease and medications alter ACE2 receptor expression in kidneys. Single cell RNA profiling of kidney biopsies from healthy living donors and patients with diabetic kidney disease revealed ACE2 expression primarily in proximal tubular epithelial cells. This cell-specific localization was confirmed by in situ hybridization. ACE2 expression levels were unaltered by exposures to renin-angiotensin-aldosterone system inhibitors in diabetic kidney disease. Bayesian integrative analysis of a large compendium of public -omics datasets identified molecular network modules induced in ACE2-expressing proximal tubular epithelial cells in diabetic kidney disease (searchable at hb.flatironinstitute.org/covid-kidney) that were linked to viral entry, immune activation, endomembrane reorganization, and RNA processing. The diabetic kidney disease ACE2-positive proximal tubular epithelial cell module overlapped with expression patterns seen in SARS-CoV-2–infected cells. Similar cellular programs were seen in ACE2-positive proximal tubular epithelial cells obtained from urine samples of 13 hospitalized patients with COVID-19, suggesting a consistent ACE2-coregulated proximal tubular epithelial cell expression program that may interact with the SARS-CoV-2 infection processes. Thus SARS-CoV-2 receptor networks can seed further research into risk stratification and therapeutic strategies for COVID-19–related kidney damage.
AB - COVID-19 morbidity and mortality are increased via unknown mechanisms in patients with diabetes and kidney disease. SARS-CoV-2 uses angiotensin-converting enzyme 2 (ACE2) for entry into host cells. Because ACE2 is a susceptibility factor for infection, we investigated how diabetic kidney disease and medications alter ACE2 receptor expression in kidneys. Single cell RNA profiling of kidney biopsies from healthy living donors and patients with diabetic kidney disease revealed ACE2 expression primarily in proximal tubular epithelial cells. This cell-specific localization was confirmed by in situ hybridization. ACE2 expression levels were unaltered by exposures to renin-angiotensin-aldosterone system inhibitors in diabetic kidney disease. Bayesian integrative analysis of a large compendium of public -omics datasets identified molecular network modules induced in ACE2-expressing proximal tubular epithelial cells in diabetic kidney disease (searchable at hb.flatironinstitute.org/covid-kidney) that were linked to viral entry, immune activation, endomembrane reorganization, and RNA processing. The diabetic kidney disease ACE2-positive proximal tubular epithelial cell module overlapped with expression patterns seen in SARS-CoV-2–infected cells. Similar cellular programs were seen in ACE2-positive proximal tubular epithelial cells obtained from urine samples of 13 hospitalized patients with COVID-19, suggesting a consistent ACE2-coregulated proximal tubular epithelial cell expression program that may interact with the SARS-CoV-2 infection processes. Thus SARS-CoV-2 receptor networks can seed further research into risk stratification and therapeutic strategies for COVID-19–related kidney damage.
KW - ACE inhibitors
KW - COVID-19
KW - SARS-CoV-2
KW - acute kidney injury
KW - diabetic nephropathy
KW - molecular networks
KW - proximal tubules
KW - scRNAseq
UR - http://www.scopus.com/inward/record.url?scp=85095824858&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85095824858&partnerID=8YFLogxK
U2 - 10.1016/j.kint.2020.09.015
DO - 10.1016/j.kint.2020.09.015
M3 - Article
C2 - 33038424
AN - SCOPUS:85095824858
VL - 98
SP - 1502
EP - 1518
JO - Kidney International
JF - Kidney International
SN - 0085-2538
IS - 6
ER -